33 research outputs found
Morpholino Gene Knockdown in Adult Fundulus heteroclitus: Role of SGK1 in Seawater Acclimation
The Atlantic killifish (Fundulus heteroclitus) is an environmental sentinel organism used extensively for studies on environmental toxicants and salt (NaCl) homeostasis. Previous research in our laboratory has shown that rapid acclimation of killifish to seawater is mediated by trafficking of CFTR chloride channels from intracellular vesicles to the plasma membrane in the opercular membrane within the first hour in seawater, which enhances chloride secretion into seawater, thereby contributing to salt homeostasis. Acute transition to seawater is also marked by an increase in both mRNA and protein levels of serum glucocorticoid kinase 1 (SGK1) within 15 minutes of transfer. Although the rise in SGK1 in gill and its functional analog, the opercular membrane, after seawater transfer precedes the increase in membrane CFTR, a direct role of SGK1 in elevating membrane CFTR has not been established in vivo. To test the hypothesis that SGK1 mediates the increase in plasma membrane CFTR we designed two functionally different vivo-morpholinos to knock down SGK1 in gill, and developed and validated a vivo-morpholino knock down technique for adult killifish. Injection (intraperitoneal, IP) of the splice blocking SGK1 vivo-morpholino reduced SGK1 mRNA in the gill after transition from fresh to seawater by 66%. The IP injection of the translational blocking and splice blocking vivo-morpholinos reduced gill SGK1 protein abundance in fish transferred from fresh to seawater by 64% and 53%, respectively. Moreover, knock down of SGK1 completely eliminated the seawater induced rise in plasma membrane CFTR, demonstrating that the increase in SGK1 protein is required for the trafficking of CFTR from intracellular vesicles in mitochondrion rich cells to the plasma membrane in the gill during acclimation to seawater. This is the first report of the use of vivo-morpholinos in adult killifish and demonstrates that vivo-morpholinos are a valuable genetic tool for this environmentally relevant model organism
ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ : ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠΌΠΈ Π΄Π°Π½Π½ΡΠΌΠΈ
Objective: to evaluate the expression levels of miRNA (miR-27, miR-101, miR-142, miR-339 and miR-424) and its relationship with clinical and laboratory parameters in lung transplant recipients. Materials and methods. The study included 57 lung recipients aged 10 to 74 years (35 Β± 15), including six children (9%) β four boys 10, 12, 13 and 17 years and girls 13 and 14 years old β and 51 adult recipients, including 30 men (62.5%). The control group was made up of 14 healthy individuals that were not significantly different by gender and age. Expression levels of the microRNAs studied in blood plasma were determined via quantitative polymerase chain reaction (PCR). Correlations of miRNA expression levels with complete blood count and biochemical blood test indicators were analyzed. Results. Patients with end-stage chronic respiratory failure (potential lung recipients) were found to have significantly higher expression levels of miR-27, miR-101 and miR-339 in plasma than the healthy individuals (p = 0.02, p = 0.03 and p = 0.01, respectively). The expression level of miR-339 correlated with the age of potential lung recipients (p = 0.04). It was a negative correlation (r = β0.46). The expression levels of the other four miRNAs were age independent. The average expression level of miR-424 in lung recipients in the long-term period after lung transplant was higher than in waitlisted patients (p = 0.03). Analysis of the relationship between miRNA expression levels and external respiration function in the long-term post-transplant period showed that miR-142 expression level (r = 0.61; p = 0.04) positively correlates with the Tiffeneau-Pinelli index. This strong correlation, which exceeds 85%, indicates the presence of restrictive lung diseases. A year and more after transplantation, it was found that in the recipients, there were close positive correlations between miR-27, miR-142, miR-424 expression levels and blood leukocyte concentration, as well as between the miR-142 expression level and the sCD40L concentration during this period. Conclusion. A comparative study of the expression level of miRNAs (miR-27, miR-101, miR-142, miR-339 and miR-424) in the blood plasma of patients suffering from end-stage chronic lung diseases of various origin and in lung recipients enables us to conclude that further studies of the miRNA panels are needed in order to assess their effectiveness as potential molecular and genetic markers of post-transplant complications.Π¦Π΅Π»Ρ: ΠΎΡΠ΅Π½ΠΈΡΡ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ (miR-27, miR-101, miR-142, miR-339 ΠΈ miR-424) ΠΈ Π΅Π΅ ΡΠ²ΡΠ·Ρ Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠΌΠΈ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π»Π΅Π³ΠΊΠΈΡ
. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 57 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 10 Π΄ΠΎ 74 Π»Π΅Ρ (Π² ΡΡΠ΅Π΄Π½Π΅ΠΌ 35 Β± 15), ΡΡΠ΅Π΄ΠΈ ΠΊΠΎΡΠΎΡΡΡ
ΡΠ΅ΡΡΠ΅ΡΠΎ Π΄Π΅ΡΠ΅ΠΉ (9%) β ΡΠ΅ΡΡΡΠ΅ ΠΌΠ°Π»ΡΡΠΈΠΊΠ° 10, 12, 13 ΠΈ 17 Π»Π΅Ρ ΠΈ Π΄Π΅Π²ΠΎΡΠΊΠΈ 13 ΠΈ 14 Π»Π΅Ρ β ΠΈ 51 Π²Π·ΡΠΎΡΠ»ΡΠΉ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½Ρ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ 30 ΠΌΡΠΆΡΠΈΠ½ (62,5%). ΠΡΡΠΏΠΏΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 14 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π»ΠΈΡ, Π·Π½Π°ΡΠΈΠΌΠΎ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°ΡΡΠΈΡ
ΡΡ ΠΏΠΎ ΠΏΠΎΠ»Ρ ΠΈ Π²ΠΎΠ·ΡΠ°ΡΡΡ. Π£ΡΠΎΠ²Π½ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ (ΠΠ¦Π ). ΠΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»ΡΡ Π°Π½Π°Π»ΠΈΠ· ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΡΡ
ΡΠ²ΡΠ·Π΅ΠΉ ΡΡΠΎΠ²Π½Π΅ΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΠΎΠ±ΡΠ΅Π³ΠΎ ΠΈ Π±ΠΈΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·ΠΎΠ² ΠΊΡΠΎΠ²ΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-27, miR-101 ΠΈ miR-339 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ (ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎ Π·Π΄ΠΎΡΠΎΠ²ΡΠΌΠΈ Π»ΠΈΡΠ°ΠΌΠΈ (Ρ = 0,02, Ρ = 0,03 ΠΈ Ρ = 0,01 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΡΠ΅ΡΡΡΠ΅Ρ
ΠΈΠ· ΠΏΡΡΠΈ Π½Π΅ Π·Π°Π²ΠΈΡΠ΅Π»Π° ΠΎΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ°. Π£ΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-339 ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π» Ρ Π²ΠΎΠ·ΡΠ°ΡΡΠΎΠΌ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
(p = 0,04), ΠΈ ΡΠ²ΡΠ·Ρ Π½ΠΎΡΠΈΠ»Π° ΠΎΠ±ΡΠ°ΡΠ½ΡΠΉ Ρ
Π°ΡΠ°ΠΊΡΠ΅Ρ, r = β0,46. Π‘ΡΠ΅Π΄Π½ΡΡ Π²Π΅Π»ΠΈΡΠΈΠ½Π° ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-424 Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
Π² ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΏΠΎΡΠ»Π΅ Π’Π ΠΎΠΊΠ°Π·Π°Π»Π°ΡΡ Π²ΡΡΠ΅, ΡΠ΅ΠΌ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΎΠΆΠΈΠ΄Π°ΡΡΠΈΡ
ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ (Ρ = 0,03). ΠΡΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠΈ ΡΠ²ΡΠ·ΠΈ ΡΡΠΎΠ²Π½Π΅ΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΡΡΠ½ΠΊΡΠΈΠΈ Π²Π½Π΅ΡΠ½Π΅Π³ΠΎ Π΄ΡΡ
Π°Π½ΠΈΡ Π² ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΠΎΠΌ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½Π°Ρ ΠΏΡΡΠΌΠ°Ρ ΡΠ²ΡΠ·Ρ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-142 (r = 0,61; p = 0,04) Ρ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠΌ Π’ΠΈΡΡΠ½ΠΎ, Π²Π΅Π»ΠΈΡΠΈΠ½Π° ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ Π±ΠΎΠ»Π΅Π΅ 85% ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ ΡΠ΅ΡΡΡΠΈΠΊΡΠΈΠ²Π½ΡΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΡΡ
Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΡΡΠ΅ΠΉ. Π§Π΅ΡΠ΅Π· Π³ΠΎΠ΄ ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π²ΡΡΠ²Π»Π΅Π½Ρ ΡΠ΅ΡΠ½ΡΠ΅ ΠΏΡΡΠΌΡΠ΅ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΡΡΠΎΠ²Π½Π΅ΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-27, miR-142 ΠΈ miR-424 Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ² Π² ΠΊΡΠΎΠ²ΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-142 Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ sCD40L Π² ΡΡΠΎΡ ΠΏΠ΅ΡΠΈΠΎΠ΄. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ (miR-27, miR-101, miR-142, miR-339 ΠΈ miR-424) Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ
Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ Π»Π΅Π³ΠΊΠΈΡ
ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠΉ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ Π² ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ, ΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ΄Π΅Π»Π°ΡΡ Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΠΎ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎΡΡΠΈ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΠ°Π½Π΅Π»ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΈΡ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ
ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΡΠ΅Π½ΠΎΠ·Π° ΡΡΠ°Ρ Π΅ΠΈ Π² ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Ρ Π±ΡΠΎΠ½Ρ ΠΎΡΠΊΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠ° Π΄ΠΎΠ½ΠΎΡΡΠΊΠΈΡ Π»Π΅Π³ΠΊΠΈΡ (ΠΏΠ΅ΡΠ²ΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π² Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ)
Lung transplantation is the final treatment option for end-stage lung failure. In 2019, 63,530 lung transplants wereΒ performed worldwide [13]. Due to the variety of diseases causing patients to resort to lung transplant surgeries,Β there is a wide range of different complications and conditions that are subject to an individual clinical approachΒ to determine treatment tactics. Each case is of great clinical interest due to the small amount of these operationsΒ and the complexity of postoperative rehabilitation, which requires a multidisciplinary approach [12]. We present aΒ report on a surgical treatment of expiratory tracheal stenosis in combination with bronchiectasis in a lung recipient.Π’ΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
β Π΅Π΄ΠΈΠ½ΡΡΠ²Π΅Π½Π½ΡΠΉ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΡΠΉ ΠΌΠ΅ΡΠΎΠ΄ Π»Π΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ Π»Π΅Π³ΠΊΠΈΡ
Π² ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉΒ ΡΡΠ°Π΄ΠΈΠΈ Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ. Π 2019 Π³ΠΎΠ΄Ρ Π² ΠΌΠΈΡΠ΅ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΎ 63 530 ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΉ Π»Π΅Π³ΠΊΠΈΡ
[13].Β Π ΡΠΈΠ»Ρ ΠΌΠ½ΠΎΠ³ΠΎΠΎΠ±ΡΠ°Π·ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΊ ΠΏΠ΅ΡΠ΅ΡΠ°Π΄ΠΊΠ΅ Π»Π΅Π³ΠΊΠΈΡ
, ΡΡΡΠ΅ΡΡΠ²ΡΠ΅Ρ ΡΠΈΡΠΎΠΊΠΈΠΉΒ ΡΠΏΠ΅ΠΊΡΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΈ ΡΠΎΡΡΠΎΡΠ½ΠΈΠΉ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΠΎΠ΄Π»Π΅ΠΆΠ°Ρ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎΠΌΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌΡ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΡΒ Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠ°ΠΊΡΠΈΠΊΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΠ°ΠΆΠ΄ΡΠΉ ΡΠ»ΡΡΠ°ΠΉ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΠΎΠ³ΡΠΎΠΌΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΊΠΈΒ Π·ΡΠ΅Π½ΠΈΡ Π² ΡΠΈΠ»Ρ Π½Π΅Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° Π΄Π°Π½Π½ΡΡ
ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉ ΠΈ ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΈ,Β ΡΡΠ΅Π±ΡΡΡΠ΅ΠΉ ΠΌΡΠ»ΡΡΠΈΠ΄ΠΈΡΡΠΈΠΏΠ»ΠΈΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° [12]. ΠΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅ΠΌΒ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠΊΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΡΠ΅Π½ΠΎΠ·Π° ΡΡΠ°Ρ
Π΅ΠΈ Π²Β ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Ρ Π±ΡΠΎΠ½Ρ
ΠΎΡΠΊΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°Β ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π»Π΅Π³ΠΊΠΈΡ
ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΡΠΈΠΎΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ Π² ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π»Π΅Π³ΠΊΠΈΡ ΠΈ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-Π»Π΅Π³ΠΎΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ°
Bronchial complications, along with development and progression of chronic dysfunction on the background of chronic rejection, are factors that reduce the quality and life of lung and heart-lung recipients. They also increase the frequency of hospitalizations. Application of cryotechnology is based on the contact effect of extremely low temperatures on organs and tissues using a cryoprobe. This article demonstrates the experience of using cryotechnology in the diagnosis and treatment of complications in lung and heart-lung recipients.ΠΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΡΠ΅ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ Π½Π°ΡΡΠ΄Ρ Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ ΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ Π½Π° ΡΠΎΠ½Π΅ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΠ²Π»ΡΡΡΡΡ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ, ΡΠ½ΠΈΠΆΠ°ΡΡΠΈΠΌΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΈ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
ΠΈ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-Π»Π΅Π³ΠΎΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ°, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°ΡΡΠΈΠΌΠΈ ΡΠ°ΡΡΠΎΡΡ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ. Π ΠΎΡΠ½ΠΎΠ²Π΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΊΡΠΈΠΎΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ Π»Π΅ΠΆΠΈΡ ΠΊΠΎΠ½ΡΠ°ΠΊΡΠ½ΠΎΠ΅ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΡΡΠ΅Π·Π²ΡΡΠ°ΠΉΠ½ΠΎ Π½ΠΈΠ·ΠΊΠΈΡ
ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡ Π½Π° ΠΎΡΠ³Π°Π½Ρ ΠΈ ΡΠΊΠ°Π½ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΊΡΠΈΠΎΠ·ΠΎΠ½Π΄Π°. Π Π΄Π°Π½Π½ΠΎΠΉ ΡΡΠ°ΡΡΠ΅ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΠ΅ΡΡΡ ΠΎΠΏΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΊΡΠΈΠΎΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
ΠΈ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-Π»Π΅Π³ΠΎΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ°
Π’ΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ Π»Π΅Π³ΠΊΠΈΡ ΠΏΡΠΈ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ: ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΠ΅ΡΠΈΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π°
Lung transplantation (LT) for idiopathic pulmonary arterial hypertension (IPAH) now is the only radical treatment of this disease.Aim: to analyze own experience of performing LT in patients with IPAH.Materials and methods. 8 adult IPAH patients, who underwent LT between 2014 and october 2018, were included. In 7 of 8 patients undergoing bilateral lung transplantation on intraoperative venoarterial extracorporeal membrane oxygenation (VA ECMO) with prolongation into the postoperative period.Results. VA ECMO support was prolonged into postoperative period 6 and 7 days respectively in 2 (25,0%) patients and 3 days in 6 (75,0%) patients. Hospital mortality in IPAH patients was 1.Conclusions. Own experience demonstrates that LT is an effective method of treatment in patients with IPAH. Hospital, 1- and 3-year survival rates for the patient collective were 87.5, 75.0 and 75.0% respectively.ΠΠ΅ΡΠ²ΠΈΡΠ½Π°Ρ Π»Π΅Π³ΠΎΡΠ½Π°Ρ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½Π°Ρ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΡ (ΠΠΠΠ) β Π½Π΅ΠΎΠ±ΡΠ°ΡΠΈΠΌΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅, Π΅Π΄ΠΈΠ½ΡΡΠ²Π΅Π½Π½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
(Π’Π).Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: Π°Π½Π°Π»ΠΈΠ· ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΡΠ° Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ Π’Π Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠΠ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠΈΠ»ΠΈ 8 Π²Π·ΡΠΎΡΠ»ΡΡ
ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ², ΠΊΠΎΡΠΎΡΡΠΌ Π±ΡΠ»Π° Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° Π’Π Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ 2014-Π³ΠΎ ΠΏΠΎ ΠΎΠΊΡΡΠ±ΡΡ 2018 Π³. ΠΡΠ΅ΠΌ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠ°ΠΌ Π±ΡΠ»Π° Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° Π΄Π²ΡΡΡΠΎΡΠΎΠ½Π½ΡΡ ΠΏΠΎΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½Π°Ρ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
. Π£ 7 ΠΈΠ· 8 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π’Π ΠΎΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»ΠΈ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΠ ΠΠΠΠ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΏΠ΅ΡΠ²ΠΈΡΠ½Π°Ρ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΡ 3-ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΠΏΠΎ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ISHLT ΡΠ°Π·Π²ΠΈΠ»Π°ΡΡ Ρ 2 (25,0%) ΠΈΠ· 8 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ², ΠΊΠΎΡΠΎΡΠ°Ρ ΠΏΡΠΎΡΠ²ΠΈΠ»Π°ΡΡ Π½Π΅Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡΡ ΠΏΡΠ΅ΠΊΡΠ°ΡΠ΅Π½ΠΈΡ ΠΠ ΠΠΠΠ. ΠΠ±ΡΠ°Ρ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΠΠΠ Ρ ΡΡΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (n = 2) ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 6 ΠΈ 7 ΡΡΡΠΎΠΊ. Π£ Π΄ΡΡΠ³ΠΈΡ
6 (75,0%) ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΡΠ°Π½Π½Π΅ΠΉ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠ΅ΡΠ΅ΡΠ°ΠΆΠ΅Π½Π½ΡΡ
Π»Π΅Π³ΠΊΠΈΡ
Π½Π΅ Π½ΠΎΡΠΈΠ»ΠΈ ΡΡΠΎΠ»Ρ Π½Π°ΠΏΡΡΠΆΠ΅Π½Π½ΠΎΠ³ΠΎ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ° (2-Ρ ΡΡΠ΅ΠΏΠ΅Π½Ρ ΠΏΠΎ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ISHLT), ΠΈ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΠΠ ΠΠΠΠ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 3 ΡΡΡΠΎΠΊ. ΠΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½Π°Ρ Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΡΡΡ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
, ΠΎΠΏΠ΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΠΠΠ, ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 1 Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘ΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΠΉ ΠΎΠΏΡΡ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΠ΅Ρ, ΡΡΠΎ Π’Π ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ Π»Π΅ΡΠ΅Π±Π½ΠΎΠΉ ΠΌΠ΅ΡΠΎΠΉ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠΠ Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΠΎΠΉ, 1- ΠΈ 3-Π»Π΅ΡΠ½Π΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ 87,5; 75,0 ΠΈ 75,0%
MicroRNA expression levels in lung recipients: correlations with clinical and laboratory data
Objective: to evaluate the expression levels of miRNA (miR-27, miR-101, miR-142, miR-339 and miR-424) and its relationship with clinical and laboratory parameters in lung transplant recipients. Materials and methods. The study included 57 lung recipients aged 10 to 74 years (35 Β± 15), including six children (9%) β four boys 10, 12, 13 and 17 years and girls 13 and 14 years old β and 51 adult recipients, including 30 men (62.5%). The control group was made up of 14 healthy individuals that were not significantly different by gender and age. Expression levels of the microRNAs studied in blood plasma were determined via quantitative polymerase chain reaction (PCR). Correlations of miRNA expression levels with complete blood count and biochemical blood test indicators were analyzed. Results. Patients with end-stage chronic respiratory failure (potential lung recipients) were found to have significantly higher expression levels of miR-27, miR-101 and miR-339 in plasma than the healthy individuals (p = 0.02, p = 0.03 and p = 0.01, respectively). The expression level of miR-339 correlated with the age of potential lung recipients (p = 0.04). It was a negative correlation (r = β0.46). The expression levels of the other four miRNAs were age independent. The average expression level of miR-424 in lung recipients in the long-term period after lung transplant was higher than in waitlisted patients (p = 0.03). Analysis of the relationship between miRNA expression levels and external respiration function in the long-term post-transplant period showed that miR-142 expression level (r = 0.61; p = 0.04) positively correlates with the Tiffeneau-Pinelli index. This strong correlation, which exceeds 85%, indicates the presence of restrictive lung diseases. A year and more after transplantation, it was found that in the recipients, there were close positive correlations between miR-27, miR-142, miR-424 expression levels and blood leukocyte concentration, as well as between the miR-142 expression level and the sCD40L concentration during this period. Conclusion. A comparative study of the expression level of miRNAs (miR-27, miR-101, miR-142, miR-339 and miR-424) in the blood plasma of patients suffering from end-stage chronic lung diseases of various origin and in lung recipients enables us to conclude that further studies of the miRNA panels are needed in order to assess their effectiveness as potential molecular and genetic markers of post-transplant complications
Lung transplantation for idiopathic pulmonary arterial hypertension: perioperational features
Lung transplantation (LT) for idiopathic pulmonary arterial hypertension (IPAH) now is the only radical treatment of this disease.Aim: to analyze own experience of performing LT in patients with IPAH.Materials and methods. 8 adult IPAH patients, who underwent LT between 2014 and october 2018, were included. In 7 of 8 patients undergoing bilateral lung transplantation on intraoperative venoarterial extracorporeal membrane oxygenation (VA ECMO) with prolongation into the postoperative period.Results. VA ECMO support was prolonged into postoperative period 6 and 7 days respectively in 2 (25,0%) patients and 3 days in 6 (75,0%) patients. Hospital mortality in IPAH patients was 1.Conclusions. Own experience demonstrates that LT is an effective method of treatment in patients with IPAH. Hospital, 1- and 3-year survival rates for the patient collective were 87.5, 75.0 and 75.0% respectively